A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis



Status:Completed
Conditions:Neurology, Dermatology, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Neurology
Healthy:No
Age Range:18 - Any
Updated:11/2/2018
Start Date:September 2014
End Date:October 17, 2018

Use our guide to learn which trials are right for you!

A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.

The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement
in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis
(dcScc) compared to matching placebo.

This study is a randomized placebo-controlled double-blind phase 2 trial of patients with
dcSSc. Eligible participants will be randomized in a 1:1 ratio to either 125 mg SC abatacept
or matching placebo, stratified by duration of dcSSc disease duration (<18 months vs >18 to
medication, followed by an additional 24 weeks of open-label SC abatacept therapy. 86
patients will be randomized in approximately 35 centers in the US, Canada and Europe, with
the goal of analyzing 74 participants. The investigators study will test whether abatacept is
statistically superior to placebo in reducing the MRSS at month 12 and explore the ability of
abatacept to prevent or reverse progression in patients with early disease duration and lower
MRSS scores, and reverse established disease in patients with longer disease duration and
higher MRSS scores.

Inclusion Criteria:

1. Diagnosis of Systematic Sclerosis (SSc), as defined using the 2013 American College of
Rheumatology/ European Union League Against Rheumatism classification of SSc

2. Diffuse Systemic Sclerosis (dcSSc) as defined by LeRoy and Medsger

3. Disease duration of ≤ 36 months (defined as time from the first non−Raynaud phenomenon
manifestation)

4. For disease duration of ≤ 18 months: ≥ 10 and ≤ 35 mRSS units at the screening visit

5. For disease duration of >18-36 months: ≥ 15 and ≤ 45 mRSS units at the screening visit
and one of the following:

- Increase ≥ 3 in mRSS units compared with the last visit within previous 1-6
months

- Involvement of one new body area with ≥ 2 mRSS units compared with the last visit
within the previous 1-6 months

- Involvement of two new body areas with ≥ 1 mRSS units compared with the last
visit within the previous 1-6 months

- Presence of 1 or more Tendon Friction Rub

6. Age ≥ 18 years at the screening visit

7. If female of childbearing potential, the patient must have a negative pregnancy test
at screening and baseline visits

8. Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs are
permitted if the patient is on a stable dose regimen for

- 2 weeks prior to and including the baseline visit.

9. ACE inhibitors, calcium-channel blockers, proton-pump inhibitors, and/or oral
vasodilators are permitted if the patient is on a stable dose for ≥ 2 weeks prior to
and including the baseline visit.

Exclusion Criteria:

1. Rheumatic disease other than dcSSc; it is acceptable to include patients with
fibromyalgia and scleroderma-associated myopathy

2. Limited cutaneous systemic sclerosis or sine scleroderma at the screening visit

3. Major surgery (including joint surgery) within 8 weeks prior to screening visit

4. Infected ulcer prior to randomization

5. Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the
investigational drug, whichever is longer) of the baseline visit

6. Previous treatment with cell-depleting therapies, including investigational agents,
including but not limited to, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and
ABA

7. Anti-CD20, and cyclophosphamide within 12 months prior to baseline visit.

8. Use of Intravenous Immunoglobulin (IVIG) within 12 weeks prior to baseline visit

9. Previous treatment with chlorambucil, bone marrow transplantation, or total lymphoid
irradiation

10. Immunization with a live/attenuated vaccine within ≤ 4 weeks prior to the baseline
visit

11. Treatment with methotrexate, hydroxychloroquine, cyclosporine A, azathioprine,
mycophenolate mofetil rapamycin, colchicine, or D-penicillamine, within≤ 4 weeks prior
to the baseline visit

12. Treatment with etanercept within ≤ 2 weeks, infliximab, certolizumab, golimumab, ABA
or adalimumab within ≤ 8 weeks, anakinra within ≤ 1 week prior to the baseline visit

13. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin ) ≤
40% of predicted at the screening visit

14. Pulmonary arterial hypertension (PAH) as determined by right heart catheterization or
on PAH approved medications for PAH. It is acceptable to use PDFE-5 inhibitors for
Raynaud's and digital ulcers.

15. Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be
participants with a history of active TB within the last 3 years, even if it was
treated; a history of active TB greater than 3 years ago, unless there is
documentation that the prior anti-TB treatment was appropriate in duration and type;
current clinical, radiographic, or laboratory evidence of active TB; and latent TB
that was not successfully treated (≥ 4 weeks).

16. Positive for hepatitis B surface antigen prior to the baseline visit

17. Positive for hepatitis C antigen, if the presence of hepatitis C virus was also shown
with polymerase chain reaction or recombinant immunoblot assay prior to baseline visit

18. Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be
participants with a history of active TB within the last 3 years, even if it was
treated; a history of active TB greater than 3 years ago, unless there is
documentation that the prior anti-TB treatment was appropriate in duration and type;
current clinical, radiographic, or laboratory evidence of active TB; and latent TB
that was not successfully treated (≥ 4 weeks).

19. Any of the following at the screening visit: Hemoglobin <8.5 g/dL; WBC < 3,000/mm3 (<3
x 109/L); platelets < 100,000/mm3 (<3 x 109/L); serum creatinine > 2 x ULN; serum ALT
or AST > 2 x ULN

20. Severe skin thickening (mRSS 3) on the inner aspects of thighs, upper arms, or abdomen

21. Patients with a history of anaphylaxis to abatacept
We found this trial at
24
sites
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Tracy Frech, MD
Phone: 801-585-1380
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Soumya Chatterjee, MD
Phone: 216-444-3290
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Suzanne Kafaja, MD
Phone: 310-825-9682
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Jerry Molitor, MD
Phone: 612-626-3736
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Principal Investigator: Elana Bernstein, MD
Phone: 917-715-4675
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Robyn Domsic, MD
Phone: 412-648-7871
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Albany, New York 12203
Principal Investigator: Axia Toledo-Garcia, MD
Phone: 518-584-4953
?
mi
from
Albany, NY
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Dinesh Khanna, MD
Phone: 734-936-4555
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Boston, Massachusetts 02116
Principal Investigator: Flavia Castelino, MD
Phone: 617-724-1786
?
mi
from
Boston, MA
Click here to add this to my saved trials
One Silber Way
Boston, Massachusetts 02215
(617) 353-2000
Principal Investigator: Robert Simms, MD
Phone: 617-414-2509
Boston University Boston University is no small operation . With over 33,000 undergraduate and graduate...
?
mi
from
Boston, MA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Faye Hant, MD
Phone: 843-792-5290
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: John Varga, MD
Phone: 312-503-2338
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Ali Ajam, MD
Phone: 614-685-6987
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Great Neck, New York 11021
Principal Investigator: Sonali Narain, MD
Phone: 516-708-2556
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Maureen Mayes, MD
Phone: 713-500-7118
?
mi
from
Houston, TX
Click here to add this to my saved trials
London, Ontario
Principal Investigator: Janet Pope, MD
Phone: 519-646-6000 x61022
?
mi
from
London,
Click here to add this to my saved trials
Los Angeles, California 90045
Principal Investigator: Daniel Furst, MD
Phone: 310-297-9221
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New Brunswick, New Jersey 08831
Principal Investigator: Vivian Hsu, MD
Phone: 732-418-8484
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
535 E 70th St
New York, New York 10021
(212) 606-1000
Principal Investigator: Jessica Gordon, MD
Phone: 212-774-2133
Hospital for Special Surgery Founded in 1863, Hospital for Special Surgery is the nation
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Nora Sandorfi, MD
Phone: 215-614-4408
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Redwood City, California 94063
Principal Investigator: Lori Chung, MD
Phone: 650-725-4612
?
mi
from
Redwood City, CA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Ashima Makol, MD
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Jane Park, MD
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3700 O St NW
Washington, District of Columbia 20057
(202) 687-0100
Georgetown University Georgetown University is one of the world's leading academic and research institutions, offering...
?
mi
from
Washington,
Click here to add this to my saved trials